RFA-DC-25-005: In Vivo High-Resolution Imaging for Inner Ear Visualization (R01, Clinical Trial Optional)

RFA-DC-25-005: In Vivo High-Resolution Imaging for Inner Ear Visualization (R01, Clinical Trial Optional)

This NIH RFA is focused, technical, and practical. It supports projects that improve the ability to visualize inner ear structures in living humans with much greater resolution than current methods allow. Unlike broad imaging grants, this NOFO is explicitly tied to inner-ear physiology, anatomy, and clinical relevance, and it is open to both technical imaging research and early-stage BESH-aligned clinical studies when risk criteria are low.

The NOFO is still relevant for the 2026/2027 cycle and remains useful as an upcoming deadline opportunity because one key submission cycle closes in June 2026 and a second is listed for October 2026 (with additional review and start-date cycles mapped through 2027). The opportunity was first posted in 2025 and remains active enough for teams preparing near-term NIH submissions.

Key details at a glance

What this opportunity funds and what it explicitly does not fund

This NOFO is best understood as a targeted instrument. It is not a general funding stream for auditory health work in all forms. The call narrows to high-resolution imaging science aimed at the inner ear, including:

• Development of new non-invasive in vivo techniques with materially improved spatial, temporal, or functional resolution in humans.
• Improvement of existing methods (hardware/software/protocol-level upgrades) to increase signal quality, contrast, and diagnostic power.
• Development of imaging probes and contrast agents to visualize inner-ear structures.
• Translation-focused work that moves imaging solutions from bench/prototype toward safe clinical uptake.

The program explicitly emphasizes structure and function where prior methods are insufficient and where imaging can materially improve diagnosis and care pathways for hearing, balance, and related communication disorders.

It is not meant for broad diagnostic platforms outside this domain. The NOFO excludes:

• Proposals without realistic translation to imaging inner ear structures in humans.
• Non-mammalian work disconnected from human relevance.
• High-risk clinical trials.
• Applications proposing more than one clinical trial in a single submission.
• Applications that omit the required five-point research strategy structure.

That five-point structure is important to internal compliance and reviewer readability:

1. Specify what imaging dimension is improved (spatial, temporal, or functional).
2. Quantify likely resolution increase and explain clinical impact.
3. Give a concrete timeline and clinical pathway for use with awake patients.
4. Explain settings and decision-usefulness in clinical context.
5. Name pathologies and diagnostic or treatment implications unlocked by better imaging.

If your idea does not clearly satisfy these, the application is likely to fail before scoring.

Why this is positioned as the low-risk companion pathway

The companion opportunity for this topic is the U01 (RFA-DC-25-003) for trials that involve higher risk and stronger efficacy-oriented design. The RFA-DC-25-005 space is for low-risk, informative work that avoids high-risk/Phase III-style trajectories and avoids FDA-governed high-risk pathways unless no oversight is needed.

From the NOFO language, this distinction is operational, not just semantic:

• Allowed: low-risk human imaging studies where the trial is designed for scientific proof and translation prep, not definitive efficacy outcomes.
• Allowed: BESH projects and other scientifically basic human studies if they remain basic in scope, low risk, and consistent with NIH clinical trial definitions.
• Excluded: projects needing IND/IDE oversight, high-risk safety profiles, or high-power efficacy claims as primary purpose.

In practice, if your proposal needs regulatory-heavy risk management, adverse event complexity, or direct treatment claims, it likely belongs in a different NOFO, and you should use this one only if the technical objective remains fundamental imaging development.

Who is eligible and who should treat this as high-risk for scope

Eligibility is broad by NIH standards. The NOFO lists:

• public and private institutions of higher education,
• nonprofits (including 501(c)(3) and non-501(c)(3)),
• for-profits including small businesses,
• local government entities,
• federal government entities,
• tribal and regional organizations in eligible categories,
• and foreign organizations.

However, broad eligibility does not mean broad execution ease. Four hard compliance gates commonly trip teams:

1. Registration completion: SAM, UEI/NCAGE as needed, eRA Commons, and Grants.gov registration must be complete before submission.
2. PI/Signing Official readiness: eRA Commons account setup for PD/PI and SO can take up to two weeks.
3. One clinical trial rule: only one clinical trial allowed, and only if it remains low-risk and not efficacy-focused.
4. Clinical trial classification discipline: if your team is unsure whether the design is a clinical trial under NIH definitions, make that determination early with programmatic guidance.

The NOFO itself is explicit that applications with registration gaps are at risk of late submission and do not receive waiver discretion.

Funds, budget logic, and practical interpretation of the “$500,000 per year” cap

The funding information is one of the first sections many applicants read. For this NOFO:

• $3M was committed in FY 2025 for this RFA plus companion stream.
• $2M is planned in FY 2026 and $2M in FY 2027 (subject to appropriations).
• Per award direct costs are capped below $500,000 per year unless prior approval is obtained.

In practical terms, treat this as a program where fit and technical execution matter more than scale.

Because the cap is explicit:

• Proposals should use personnel and equipment spending to support the imaging goal directly.
• Milestone-driven budgets should be stronger than headline-heavy budgets.
• Overbuilding non-core technical support in early years can signal poor scope discipline.
• Multi-year requests should connect clearly to validation milestones and translational readiness.

The project period is not fixed; it is determined by scope up to a maximum of 5 years. That can be useful for teams proposing a phased imaging roadmap, but still requires a realistic staffing and facility plan that maps to publication and validation windows.

Application timeline and process for 2026/2027 planning

For 2026 planning, the NOFO includes multiple cycles and associated review timelines:

• June 3, 2026 submission date (current next window from the current point-in-time).
• October 1, 2026 submission date (additional cycle if June is missed or if staged strategy is preferred).
• Expiration date: October 2, 2026.

Review and award cycles in the NOFO key-date table pair each full submission set with likely peer review, council review, and earliest start windows through 2027.

Suggested planning sequence (practical)

Given the NIH intake and validation burden, teams should plan backward from June 3, 2026 if possible:

• 90–120 days before deadline: finalize technical concept, confirm whether your study is low-risk clinical trial or non-trial.
• 60 days: define imaging performance metrics, choose core collaborators (signal processing, clinical site, imaging physicist, translational pathway), and draft five-point research strategy.
• 45 days: prepare registrations and verify PI account access.
• 30 days: build full draft application and required planning sections (resource sharing, data management, human subjects/IRB/biohazards where applicable).
• 14 days: internal compliance check for page limits and NIH form instructions.
• 7 days: submit final draft early to absorb system corrections.

NIH explicitly expects early submission to reduce late-stage submission errors.

Submission systems and route

This NOFO accepts standard NIH channels:

• ASSIST
• institutional systems-to-systems
• Grants.gov Workspace

Applications are submitted electronically; hardcopy is not accepted. The applicant should use the NOFO-specific application package and the NIH How to Apply guides.

Required materials and what the reviewers will look for

The NOFO does not reward generic imaging proposals. It rewards proposals that prove translation feasibility.

Required core sections

• Standard NIH SF424(R&R) forms and profile sections.
• Full response to the five required points in Research Strategy.
• Explicit translational plan for movement to clinical settings.
• Data Management and Sharing Plan per NIH policy.
• Required sharing plans for resources if applicable.
• Human subjects/IRB and clinical safety documentation where needed.
• Vertebrate animal or biohazard documentation if included.

Clinical trial posture (if included)

If your application includes a human trial component, make sure all NIH criteria are explicitly satisfied:

• No IND/IDE requirement for the design.
• Not high-risk.
• Not designed as formal phase III-style efficacy proof.
• Designed to generate evidence informing future studies.
• At most one trial in the package.

Any proposal that sounds like efficacy proof in this pathway should not proceed under this NOFO.

Compliance and policy anchors

Beyond NIH science review, successful submission requires attention to:

• SAM.gov validity and UEI alignment.
• eRA Commons role setup for PD/PI and signing official.
• Institution-level submission authority alignment.
• Data and safety requirements for clinical work.
• ClinicalTrials.gov registration posture for applicable trials.

Skipping these does not usually disqualify by science but can fail intake and delay review.

Review criteria and how to strengthen a submission

NIH review still follows peer review structure, then council and policy checks. For this NOFO, strong applications typically have four strengths:

• Specificity of imaging gain: explain resolution gains numerically where possible.
• Feasible translational bridge: define where in the clinic this improves decisions.
• Team sufficiency: combine technical and clinical expertise.
• Scope control: avoid trying to do full productization, diagnostics, and broad commercial translation in a single grant year.

Section V applies standard impact framework plus additional topic-specific checks:

• Innovation is not enough alone; impact requires a clinical pathway.
• Rigor in study design, safety handling, and reproducibility.
• If human subjects are included, review emphasizes risk control and data validity.
• For vertebrate work, methodologic and welfare standards are weighted.

Reviewer traps to avoid

• Submitting a high-risk intervention plan under the low-risk NOFO.
• Confusing this NOFO with the companion U01 clinical trial arm.
• Omitting one of the five required research strategy points.
• Underestimating time needed for registrations and account setup.
• Over-promising translational outcomes without a realistic clinical workflow.

Projects that stay disciplined on technical novelty and clinical value, and that explain how data will drive diagnosis or treatment planning, usually resonate better than broader “imaging tool” proposals.

Common mistakes and pre-submission checklist

Use this checklist before finalizing:

• Confirm target application date and verify this NOFO is still open for the planned deadline.
• Confirm one of the two paths: non-trial project or low-risk clinical trial.
• Confirm only one clinical trial is included.
• Check that the project directly targets human inner ear resolution (not generic imaging).
• Complete NIH registration requirements early (SAM, UEI, eRA Commons, Grants.gov).
• Include all required plans: data management, resource sharing, safety, human subjects (if relevant).
• Keep budget under $500,000 direct/year unless prior approval is secured and justified.
• Build and maintain explicit milestones linked to proposed grant-year spending.
• Provide translation pathways and diagnostic context early in the narrative.

If your team must decide between this RFA and RFA-DC-25-003, a practical question is: “Can the study move forward without high-risk clinical claims or significant efficacy outcomes?” If the answer is no, the U01 route may be more compliant.

Frequently Asked Questions

Is this still useful for 2026/2027 planning now?

Yes, the NOFO includes a June 2026 submission cycle and a later 2026 cycle, with funding lines in both FY 2026 and FY 2027 depending on appropriations.

Is this only for basic science with no human work?

No. It supports both non-trial and low-risk NIH-defined clinical trial projects, provided the trial remains low-risk and limited as required by the NOFO.

Can foreign groups apply?

Yes, non-domestic organizations are listed as eligible, but they must still meet NIH policy requirements and all registration pathways.

Is this a one-year award?

No. Project period is determined by scope and can be up to 5 years.

Do I need a resource-sharing plan?

Yes. Resource sharing and data-management requirements apply broadly under NIH policy and were reinforced for this opportunity.

Is the funding guaranteed at $2M per year?

No. The NOFO indicates planned amounts based on annual appropriations; amounts are not hard guarantee of full program closure.

Official links and monitoring

Official opportunity page: https://grants.nih.gov/grants/guide/rfa-files/RFA-DC-25-005.html

Related companion opportunity (higher-risk clinical trial path): https://grants.nih.gov/grants/guide/rfa-files/RFA-DC-25-003.html

NIH application guidance references are in the same source, including submission contacts and instructions pages in the NOFO.

Because this NOFO has multi-round structure and changing NIH guidance, monitor the page for updates before finalizing your submission plan.